Clinitech Laboratory Limited (BOM:544220)
India
· Delayed Price · Currency is INR 35.20
0.00 (0.00%)
At close: Mar 9, 2026
Clinitech Laboratory Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| Revenue | 92.39 | 82.35 | 64.03 | 63.48 | 63.84 | 45.54 |
| Revenue Growth (YoY) | 24.50% | 28.61% | 0.87% | -0.58% | 40.19% | - |
| Cost of Revenue | 24.97 | 18.81 | 13.78 | 14.14 | 18.18 | 13.1 |
| Gross Profit | 67.42 | 63.54 | 50.25 | 49.33 | 45.66 | 32.45 |
| Selling, General & Admin | 30.86 | 29.23 | 23.53 | 20.32 | 17.79 | 11.64 |
| Other Operating Expenses | 28.1 | 25.69 | 16.69 | 15.49 | 17.19 | 12.57 |
| Operating Expenses | 62.85 | 59.41 | 44.61 | 40.27 | 38.78 | 26.66 |
| Operating Income | 4.58 | 4.12 | 5.64 | 9.06 | 6.88 | 5.79 |
| Interest Expense | -0.53 | -0.43 | -0.72 | -0.58 | -0.42 | -0.75 |
| Interest & Investment Income | 1.3 | 1.3 | 0.1 | 0.08 | 0.06 | 0 |
| Earnings From Equity Investments | - | - | - | 0.04 | 0.11 | 0.01 |
| Other Non Operating Income (Expenses) | 0.44 | -0.12 | -0.07 | 0.04 | 0.4 | 0.11 |
| EBT Excluding Unusual Items | 5.78 | 4.87 | 4.95 | 8.64 | 7.02 | 5.16 |
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.3 |
| Gain (Loss) on Sale of Assets | 0.68 | 0.68 | 0.11 | - | -0 | - |
| Pretax Income | 6.46 | 5.55 | 5.05 | 8.64 | 7.02 | 5.46 |
| Income Tax Expense | 1.72 | 1.6 | 1.34 | 2.51 | 1.9 | 1.43 |
| Net Income | 4.74 | 3.95 | 3.71 | 6.13 | 5.13 | 4.02 |
| Net Income to Common | 4.74 | 3.95 | 3.71 | 6.13 | 5.13 | 4.02 |
| Net Income Growth | -9.65% | 6.33% | -39.45% | 19.61% | 27.39% | - |
| Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 2 | 1 |
| Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 2 | 1 |
| Shares Change (YoY) | - | 32.88% | 4.44% | - | - | - |
| EPS (Basic) | 1.97 | 1.90 | 2.37 | 4.09 | 3.42 | 2.68 |
| EPS (Diluted) | 1.97 | 1.90 | 2.37 | 4.09 | 3.42 | 2.68 |
| EPS Growth | - | -19.98% | -42.03% | 19.61% | 27.39% | - |
| Free Cash Flow | -10.54 | -20.43 | -24.88 | 9.68 | -5.58 | 1.87 |
| Free Cash Flow Per Share | -4.38 | -9.82 | -15.88 | 6.45 | -3.72 | 1.25 |
| Gross Margin | 72.98% | 77.16% | 78.47% | 77.72% | 71.52% | 71.25% |
| Operating Margin | 4.95% | 5.01% | 8.80% | 14.27% | 10.77% | 12.71% |
| Profit Margin | 5.13% | 4.79% | 5.80% | 9.66% | 8.03% | 8.84% |
| Free Cash Flow Margin | -11.41% | -24.81% | -38.86% | 15.24% | -8.73% | 4.11% |
| EBITDA | 8.46 | 8.62 | 9.97 | 13.52 | 10.69 | 8.24 |
| EBITDA Margin | 9.16% | 10.47% | 15.57% | 21.30% | 16.74% | 18.10% |
| D&A For EBITDA | 3.88 | 4.5 | 4.34 | 4.46 | 3.81 | 2.45 |
| EBIT | 4.58 | 4.12 | 5.64 | 9.06 | 6.88 | 5.79 |
| EBIT Margin | 4.95% | 5.00% | 8.80% | 14.27% | 10.77% | 12.71% |
| Effective Tax Rate | 26.62% | 28.83% | 26.52% | 29.02% | 27.00% | 26.26% |
| Revenue as Reported | 95.23 | 84.63 | 64.39 | 63.63 | 64.57 | 45.96 |
| Advertising Expenses | - | 0.62 | 0.65 | - | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.